RxDoctor Payments Data

Ronald Smith, MD

Internal Medicine · West Chester, OHNPI 1700814001

Payments from drug & device makers

$215in general payments, 2019–2025

Across 11 payments — averaging $19.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$63
  • Lilly USA, LLC$43
  • Eisai Inc.$33
  • Abbott$22
  • Pfizer$20
  • AbbVie$19
  • plus $15 from 1 others

What the payments were for

  • Food & beverage$215100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk3$63
Lilly USA, LLC2$43
Eisai Inc.2$33
Abbott1$22
Pfizer1$20
AbbVie1$19
AstraZeneca1$15

How this compares

$215 in reported general payments places this provider in the 50th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$69,649
Medicare patients
222
Services billed
884

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin42$53,485
JanuviaSitagliptin Phosphate31$43,682
EliquisApixaban64$42,154
TrulicityDulaglutide29$39,649
OzempicSemaglutide24$22,865
Tresiba Flextouch U-100Insulin Degludec16$20,419
Lantus SolostarInsulin Glargine,hum.Rec.Anlog112$17,833
FarxigaDapagliflozin Propanediol16$15,035
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$13,032
XareltoRivaroxaban12$8,242
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$6,946
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$6,796
Novolog FlexpenInsulin Aspart27$6,457
Atorvastatin Calcium583$3,960
Insulin Lispro Kwikpen U-100Insulin Lispro19$3,504

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$20$42,15464 claims
Lilly USA, LLCTrulicity$43$39,64929 claims
Novo NordiskOzempic$63$22,86524 claims
AstraZenecaFarxiga$15$15,03516 claims
AbbVieSynthroid$19$1,91549 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in West Chester

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →